Quick Answer
Gain Therapeutics, Inc. reported Cash and Equivalents of $20.84 million for fiscal year 2025.
Gain Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $20.84M | +100.6% |
| 2024 | $10.39M | -11.9% |
| 2023 | $11.79M | +61.3% |
| 2022 | $7.31M | -80.2% |
| 2021 | $36.88M | +392.2% |
| 2020 | $7.49M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.81M | -26.9% | +31.6% |
| June 30, 2025 | $6.69M | -60.5% | -26.2% |
| March 31, 2025 | $9.07M | -14.8% | -12.7% |
| December 31, 2024 | $10.39M | -11.9% | -13.8% |
| September 30, 2024 | $12.05M | +182.0% | -28.9% |
| June 30, 2024 | $16.94M | +168.0% | +59.2% |
| March 31, 2024 | $10.64M | +77.7% | -9.8% |
| December 31, 2023 | $11.79M | +61.3% | +176.1% |
- Gain Therapeutics, Inc. showed an increase of +100.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Gain Therapeutics, Inc.’s cash and equivalents has grown by 178.1% (from $7.49 million to $20.84 million).
- The most recent figure is from Gain Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: